Pilot & Feasibility Program

飞行员

基本信息

批准号：
7925282
负责人：
JOEL F HABENER
金额：
$ 43.76万
依托单位：
MASSACHUSETTS GENERAL HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-05-01 至 2015-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7925282
关键词：
Area Australia Award Benchmarking Boston Clinical Communities Data Development Diabetes Mellitus Discipline Eligibility Determination Endocrinology Exhibits Eye Foundations Funding Future Genomics Germany Goals Grant Grant Review Home environment Immunology Institution Instruction Internet Investigation K-Series Research Career Programs Mails Measures Metabolism Mission Molecular and Cellular Biology NIH Program Announcements Process Productivity Publications Publishing Recording of previous events Recruitment Activity Reporting Research Research Institute Research Personnel Research Proposals Research Support Research Training Resources Review Committee Seeds Series Source Time Training Programs Translational Research United States National Institutes of Health Work base career clinical care cohort density effectiveness measure innovation lectures member novel post-doctoral training posters programs success symposium web site

项目摘要

The Pilot and Feasibilty (P&F) grant program aims to provide initial support for meritorious research relevant to diabetes and its complications. Specifically, the program seeks to recruit new investigators and/or new ideas into diabetes research by providing seed funding for innovative lines of investigation so as to enable the awardees to generate substantial preliminary data. It is anticipated that one or two years support at the level of $35,000/year will strongly promote the likelihood of obtaining longer-term support. P&F grant availability and the criteria for eligibility are detailed in the program announcements, which are distributed repeatedly through poster mailings and internet to all area research institutions between December and January. Eligibility criteria, instructions and application materials are featured prominently on the BADERC web site. During the previous five years cycle, 106 completed applications were received; most originated from MGH (38), with significant numbers from BIDMC(17) BWH (15) BMC (18), Joslin (7),Tufts (5) Schepens Eye Research Institute (4) and single applications from others. All grants receive outside review, with two reports received for -70%. The grants and reviews were further evaluated by the BADERC executive committee, who based final funding decisions primarily on reviewer merit scores; when scores are close however, issues of BADERC mission relevance and fair distribution among disciplines and institutions are considered. The distribution of the 19 grants awarded this cycle has favored MGH (10) and BIDMC (5); 45/106 applications focused on metabolism, as did 10/19 P&F grants awarded. Five of 24 Clinical/Translaional applications were funded but none of the immunology proposals, a change from the previous cycle. As to subsequent funding history, of the 29 awardees between 2000-2008 who were considered "new" investigators at the time of their P&F award, 14 have achieved ROI-level funding and 11 achieved ADA/JDRF/foundation awards. This cohort of investigators published of 5-6 publications subsequent to acquiring the P&F award. We consider the P&F grant largely successful in achieving the goals articulated. In the future, the BADERC internal review committee will expand from three to six members to enhance representation.

试点和可行性 (P&F) 资助计划旨在为与糖尿病及其并发症相关的优秀研究提供初步支持。具体来说，该计划旨在通过为创新研究方向提供种子资金，招募新的研究人员和/或新的想法进入糖尿病研究，以使获奖者能够生成大量的初步数据。预计一到两年 35,000 美元/年的支持将大大提高获得长期支持的可能性。 P&F 补助金的可用性和资格标准在已分发的计划公告中有详细说明 12 月至 1 月期间，通过海报邮寄和互联网向所有地区研究机构反复进行了研究。资格标准、说明和申请材料在 BADERC 网站上的显着位置列出。在过去的五年周期中，共收到 106 份已完成的申请；大多数来自 MGH (38)，其中大量来自 BIDMC(17) BWH (15) BMC (18)、Joslin (7)、塔夫茨大学 (5)、Schepens 眼科研究所 (4) 以及其他机构的单一申请。所有赠款均接受外部审查，收到两份报告，费用为 -70%。 BADERC 执行委员会进一步评估了资助和审查，该委员会主要根据审查者的评分做出最终的资助决定；然而，当分数接近时，就会考虑 BADERC 任务的相关性以及学科和机构之间的公平分配问题。本周期授予的 19 项拨款的分配有利于 MGH (10) 和 BIDMC (5)； 45/106 份申请重点关注新陈代谢，10/19 份 P&F 拨款也是如此。 24 项临床/转化申请中有 5 项获得资助，但没有一项免疫学提案获得资助，这与上一周期有所不同。至于随后的资助历史，在 2000 年至 2008 年期间被认为是“新”研究者的 29 名获奖者中，有 14 人获得了 ROI 级别的资助，11 人获得了 ADA/JDRF/基金会奖项。这群研究人员在获得 P&F 奖后发表了 5-6 篇出版物。我们认为 P&F 赠款在实现所阐明的目标方面取得了很大成功。未来，BADERC内部审查委员会成员将从三人扩大到六人，以增强代表性。